Floatz logo

Duvelisib

T-Cell Prolymphocytic Leukemia

Jonsson Comprehensive Cancer CenterSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the T-Cell Prolymphocytic Leukemia cohort.

Asset / SponsorPhaseRating
Cytosin-Arabinosid
M.D. Anderson Cancer Center
Phase 2BB
Cyclophosphamide
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2BB
Fludarabine
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3BB
CYCLOSPORIN A
Fred Hutchinson Cancer Center
Phase 3BB
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BB

View all 28 →

Same molecule, other indications

Duvelisib is also rated in:

chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
B
Indicative ·
60 / 100
View asset →
follicular lymphomaDormant
B
Indicative ·
56 / 100
View asset →
indolent B-cell non-Hodgkin lymphomaDormant
B
Indicative ·
56 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →